Altered MABA profiles correlate with T2D, obesity and inflammatory bowel disease; experimental data indicate improved glucose homeostasis and reduced adiposity with specific MABAs; potential to modulate gut–brain signaling via GLP-1 and FGF19. The gene discussed is FGF19; the disease is inflammatory bowel disease.